PDCD1 and osteosarcoma: For instance, Shi et al. observed that the PI3Kδ/γ inhibitor SNA, by reducing MDSCs activity, improved the TME and augmented the effectiveness of anti-PD1 therapy, especially stressing the crucial role of CD8+ T cells’ activation in osteosarcoma (Shi et al., 2019).